Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Eleanor Malone
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?
Emerging Company Profile: CHF16m for firm that liposomes to capture toxins and protect the organs of patients with acute liver failure.
Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.
AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.
DAPA-HF data on AstraZeneca’s SGLT-2 inhibitor dapagliflozin as a treatment for heart failure in both diabetics and non-diabetics won spontaneous applause at ESC.